SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Ox who wrote (1238)11/13/2001 4:40:32 PM
From: tuck  Read Replies (1) of 1321
 
Michael,

Excuse me? This is taken from the the subject post of this thread:

>>The submission also included very encouraging data from a second
study of PHOTOFRIN(R) in 17 patients with completely obstructing
esophageal cancer who were considered to have no other acceptable
treatment options. All patients who receive PHOTOFRIN(R) will be
photosensitive until the drug has cleared from the body and are
advised to protect themselves from exposure to direct sunlight or
bright lights.<<

snip

edit: and from QLT's own site:

qltinc.com

I don't follow the company super closely, have they dropped this already?

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News